Agenda
The IBC 2024 Meeting will feature three key topic tracks:
Plenary sessions and breaks will bring together all attendees to allow multidisciplinary networking. The 2024 agenda will be confirmed soon, Explore the full agenda from 2023 for each track below.
MBL-CLL/Low-grade Lymphoma
*All times are in est
Mar
Fri 03
Welcome and introductions – Plenary
Technical Break
Topic 1.1 Biology of precursor CLL and FL conditions
Moderators: Sandrine Roulland
- Genomic sequencing in MBL: Susan Slager
- Germline risk determination for progression from MBL (-low to -high), including intra-patient changes in their clonal genetic profile in MBL-low
- Familial MBL-CLL and implications for risk of MBL progression
- Early FL precursors: in-situ follicular neoplasia and follicular lymphoma-like cells: Sandrine Roulland
Panel discussion – all speakers
Topic 1.2: The role of MBL in the etiology of CLL
Moderators: Tait Shanafelt
- Low- and high-count MBL: Prevalence and consequences: Andrew Rawstron
- How to differentiate:
- clinical consequences of low-/high-count MBL assessment
- Low-count MBL in African versus European/North American MBL populations
- How to differentiate:
- Impact of CLL cell surface IgM levels on disease progression and escape of BTK inhibition: Francesco Forconi
Panel discussion – all speakers
Topic 1.3: Precursor conditions in Waldenström Macroglobulinemia
Moderators: Paolo Ghia
- Pre-neoplastic somatic mutations and malignant transformation of Waldenström Macroglobulinemia: Bruno Paiva
- CBL-MZ; precursor of SMZL: Kostas Stamatopoulos
Panel discussion – all speakers
Welcome reception/buffet
Mar
Sat 04
Welcome and outline of the day (plenary): Irene Ghobrial and Jesús San-Miguel
Technical break
Session 2: A focus on the indolent-to-aggressive transition in blood cancers
Topic 2.1: Overview of progression in MBL
Moderators: Paolo Ghia
- Early/highly sensitive detection of MBL: Julia Almeida
- The BCR repertoire in MBL vs CLL: role in disease progression: Kostas Stamatopoulos
- Immune dysregulation in MBL (potential for inclusion of data on the frequency of MBL in patients with COVID-19): Alberto Órfão
Panel discussion – all attendees
Break
Topic 2.2: Indolent to aggressive: Progression of CLL and FL
Moderators: Tait Shanafelt
- Technologies for detecting progression: Single-cell analysis technologies in CLL: Giovanni Tonon
- Early detection of risk-of-progression of CLL to Richter syndrome: Iñaki Martín-Subero
- Role of the microenvironment in FL pathogenesis and progression: TBC
- Progression of indolent FL to aggressive lymphomas: Miguel Alcoceba
Panel discussion – all speakers
Session 3: Opportunities for therapeutic intervention in early CLL
Topic 3.1: Overview of ongoing clinical studies and preliminary data
Moderators: Matthew Davids
- Ibrutinib in a patient population who would otherwise not meet the inclusion criteria for existing CLL clinical trials – trial overview and preliminary data: Petra Langerbeins
- Preliminary data from the NeoVax CLL study in patients otherwise excluded from clinical trials in CLL – development of a personalized vaccine: Inhye Ahn
- Venetoclax + obinutuzumab in early high-risk CLL: early versus later treatment initiation – study design ahead of anticipated data: Deborah Stephens
Panel discussion – all speakers
Lunch break
Keynote: FDA presentation (plenary session): Nicole Gormley
Technical break
Session 4: T-cell clones of uncertain significance (TCUS)
Topic 4.1: TCUS and T-cell LGL leukemia – laboratory diagnostics
Moderators: Alberto Órfão
- TCUS and T-cell LGL leukemia – implications for laboratory diagnostics: Julia Almeida
- STAT-pathway mutations in the pathogenesis of T-LGL leukemia: Thomas Loughran
- Morphologic, immunophenotypic and molecular features of T-LGL leukemia – therapeutic implications: Gianpietro Semenzato
Panel discussion – all speakers
Technical break
Roundtable discussion – myeloma, CHIP/CCUS, MBL-CLL and lymphomas
Moderators: Matthew Davids, Kenneth Anderson and George Vassiliou
- Populations at risk for progression and concepts of interception
- Current end points of clinical trials in early interception in CCU and CLL, and where to go from there
- Should we be screening for CHIP, MBL, MGUS, and who to screen?
Group photo
Faculty dinner
Mar
Sun 05
Plenary: Presentation of key points – sharing from each disease track
Panel discussion
Thematic discussions
Summary conclusions and end of meeting: Irene Ghobrial and Jesús San-Miguel
END
CHIP/MDS
*All times are in est
Mar
Fri 03
Welcome and introductions – Plenary
Technical Break
Session 1: Mechanisms of clonal expansion and transformation
Topic 1.1 Genomics/observational
Moderators: George Vassiliou and Siddhartha Jaiswal
- Natural History/dynamics: George Vassiliou
- Genetic predisposition: Siddhartha Kar
- Ageing and clonal expansion rate: Alexander Bick
- Copy number: Jamie Blundell
Panel discussion – all speakers
Topic 1.2: Molecular mechanisms
Moderators: George Vassiliou and Siddhartha Jaiswal
- Implications of germline TCL1A variants: Siddhartha Jaiswal
- Myeloid/lymphoid somatic gene mutations and risk of hematologic malignancy: Lachelle Weeks
- Acquisition of driver mutations in DNM3TA as a precursor to CH: Elisa Laurenti
- Driver mutations in DNM3TA or implications of PPM1D clonal mutations: Liran Shlush
Panel discussion – all speakers
Welcome reception/buffet
Mar
Sat 04
Welcome and outline of the day (plenary): Irene Ghobrial and Jesús San-Miguel
Technical break
Session 2: Risk factors and predictive modelling
Topic 2.1: Prediction of adverse outcomes
Moderators: Luca Malcovati
- Predictive models – Lesson from population-based studies: Lachelle Weeks
- Context-dependent risk factors – CH and exposure to genotoxic agents: Kelly Bolton
Panel discussion – all attendees
Break
Topic 2.2: Clonal hematopoiesis in the clinics
Moderators: Lambert Busque and Felipe Prósper
- CHIP, CCUS and early MDS – clinical classification and predictive models: Luca Malcovati
- CHIP clinic: who, when, how?: Eric Padron
- CHIP and genetic predisposition: Lucy Godley
Panel discussion – all speakers
Session 3: Early intervention
Topic 3.1: Pre-clinical
Moderators: Kelly Bolton
- Epigenetic studies: John Pimanda
- Mechanisms of immune evasion in myeloid malignancies: Iannis Aifantis
- Pre-clinical studies targeting clonal hematopoiesis HSPCs: Ravi Majeti
- RNA splicing: Omar Abdel-Wahab
Panel discussion – all speakers
Lunch break
Keynote: FDA presentation (plenary session): Nicole Gormley
Technical break
Topic 3.2: Clinical
Moderators: Kelly Bolton and Kirsten Grønbaek
- Vitamin C: Mrinal Patnaik
- Oral vitamin C and Metformin in CCUS: Kirsten Grønbaek
- Anti-IL1: Uma Borate
Panel discussion – all speakers
Technical break
Roundtable discussion – Myeloma, CHIP/CCUS, MBL-CLL and lymphomas
Moderators: Matthew Davids, Kenneth Anderson and George Vassiliou
- Populations at risk for progression and concepts of interception
- Current end points of clinical trials in early interception in CCU and CLL, and where to go from there
- Should we be screening for CHIP, MBL, MGUS, and who to screen?
Group photo
Faculty dinner
Mar
Sun 05
Plenary: Presentation of key points – sharing from each disease track
Panel discussion
Thematic discussions
Summary conclusions and end of meeting: Irene Ghobrial and Jesús San-Miguel
END
MM/SMM/MGUS
*All times are in est
Mar
Fri 03
Welcome and introductions – Plenary
Technical Break
Session 1: Uncovering mechanisms of transformation
Keynote: The interplay between genes and the immune system: Kenneth Anderson
Topic 1.1 Genomics of MGUS and SMM
Moderators: Gareth Morgan
- Genomics of transformation: Francesco Maura
- Epigenetics of transformation: Felipe Prósper
- Molecular classification of SMM: Irene Ghobrial
Panel discussion – all speakers
Topic 1.2: Animal models to study disease progression
Moderators: Leif Bergsagel and Irene Ghobrial
- Immune recapitulation: Madhav Dhodapkar
- Genetic transition under immunocompetence: José Ángel Martínez Climent
- In vivo model systems and the interaction between clonal hematopoiesis and plasma cell neoplasms: Adam Sperling
Panel discussion – all speakers
Topic 1.3: Immune microenvironment of MGUS and smoldering myeloma
Moderators: Kenneth Anderson and Bruno Paiva
- Early immune derailment: Gad Getz
- Immune biomarkers of response to therapy, immune MRD: Romanos Sklavenitis-Pistofidis
- Metabolomics and the immune system: Urvi Shah
Panel discussion – all speakers
Welcome reception/buffet
Mar
Sat 04
Welcome and outline of the day (plenary): Irene Ghobrial and Jesús San-Miguel
Technical break
Session 2: Risk factors and risk models for progression
Topic 2.1: MGUS/SMM screening and risk
Moderators: Rafael Fonseca and María-Victoria Mateos
- Natural history of MGUS: Rafael Fonseca
- iStopMM: Sigurður Kristinsson
- African Americans and family studies perspective including the PROMISE study: Catherine Marinac
- Is MGUS a benign disease? MGUS of clinical significance (MGRS, Neuropathy): Angela Dispenzieri
Panel discussion – all speakers
Break
Topic 2.2: Risk factors and classification in SMM
Moderators: Meletios Dimopoulos and Shaji Kumar
- Progress from the 20/20/20 classification: Elizabeth O’Donnell
- Immune biomarkers and circulating tumor cells: Bruno Paiva
- Clinical and bone biomarkers including the PANGEA model: Efstathios Kastritis
- Biomarkers to predict risk of AL amyloidosis: Mario Nuvolone
Panel discussion – all speakers
Section 3: Is it the right time for early treatment intervention?
Topic 3.1: Clinical trials
Moderators: Jesús San-Miguel
- Phase 2 trials: Shaji Kumar
- Phase 3 trials: María-Victoria Mateos
- Novel drugs and combinations: Salomon Manier
- Trials in immunotherapy: Omar Nadeem
Panel discussion – all speakers
Lunch break
Keynote: FDA presentation (plenary session): Nicole Gormley
Technical break
Topic 3.2: Roundtable discussion on smoldering myeloma
Moderators: Kenneth Anderson
- This is a round table discussion that will include the FDA, biotech, academia and foundations.
Topics that will be discussed:
– Inclusion criteria
– Duration of therapy
– Primary endpoints
– Progression post-therapy in SMM
– Access to clinical trials
– Quality of life measures
Technical break
Roundtable discussion – myeloma, CHIP/CCUS, MBL-CLL and lymphomas
Moderators: Matthew Davids, Kenneth Anderson and George Vassiliou
- Populations at risk for progression and concepts of interception
- Current end points of clinical trials in early interception in CCU and CLL, and where to go from there
- Should we be screening for CHIP, MBL, MGUS, and who to screen?
Group photo
Faculty dinner
Mar
Sun 05
Plenary: Presentation of key points – sharing from each disease track
Panel discussion
Thematic discussions
Summary conclusions and end of meeting: Irene Ghobrial and Jesús San-Miguel
END